Targeting myeloid cells for regulation of alum-based immunity

靶向骨髓细胞调节明矾免疫

基本信息

  • 批准号:
    9897437
  • 负责人:
  • 金额:
    $ 65.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Alum is the most widely used adjuvant in current subunit vaccines against infectious agents. Mucosal tissues represent the main portal of entry of pathogens. In contrast with the general bloodstream in the systemic compartment, mucosal tissues contain a large number of IgA producing cells. This immunoglobulin isotype contributes to the protection of exposed mucosal surfaces via a number of mechanisms including prevention of pathogen binding to host cells (epithelial cells and dendritic cells), neutralization of toxins in the lumen, and neutralization of viruses within epithelial cells. Injected vaccines can induce high levels of IgG responses in the bloodstream, but they are not effective at inducing secretory IgA responses which are needed for optimal protection of mucosal surfaces. In contrast with injected vaccines, mucosal vaccines delivered through the oral, rectal, nasal or sublingual routes target Mucosal-Associated Lymphoid Tissues where they can induce innate signals necessary for induction of secretory IgA responses. Despite decades of research on mucosal vaccines, to date, only two oral vaccines and one intranasal vaccine are licensed for use in the US. This proposal will address the overall hypothesis that the adjuvant alum triggers innate signals that restrict the breath of antibody responses and prevent the production of IgA. Our newly generated data suggest that a family of molecules produced by myeloid cells plays a central role in preventing IgA production by alum-based injected vaccines and targeting those molecules will improve protection by increasing IgA production. Aim 1 will focus on the mechanisms underlying innate suppression of IgA responses by myeloid cells in non-mucosal sites. Aim 2 will identify the cells and signaling pathways targeted by pharmacological agents inhibiting this family of molecules to regulate induction of systemic and mucosal immune responses after systemic immunization. Aim 3 will establish whether strategies targeting the innate suppressors of IgA responses promote broad systemic and mucosal immunity and can protect a relevant animal model against infection with an enteric virus.
明矾是目前抗感染原亚单位疫苗中使用最广泛的佐剂。粘膜组织 是病原体进入的主要门户。与全身的一般血流相比, 粘膜组织含有大量的伊加产生细胞。这种免疫球蛋白同种型 有助于通过多种机制保护暴露的粘膜表面, 病原体与宿主细胞(上皮细胞和树突细胞)结合,中和管腔中的毒素,以及 中和上皮细胞内的病毒。注射疫苗可在小鼠中诱导高水平的IgG应答。 它们可以促进血液循环,但它们不能有效诱导分泌型IgA应答,而分泌型IgA应答是最佳免疫调节所需的。 保护粘膜表面。与注射疫苗相比,粘膜疫苗通过口腔, 直肠、鼻腔或舌下途径靶向粘膜相关类肉瘤组织,在那里它们可以诱导先天性 诱导分泌型伊加应答所必需的信号。尽管对粘膜疫苗进行了数十年的研究, 到目前为止,只有两种口服疫苗和一种鼻内疫苗在美国获得许可使用。这项建议会 解决了佐剂明矾触发限制抗体呼吸的先天信号的总体假设 反应和防止伊加的产生。我们最新的数据表明, 由骨髓细胞产生的IgA在防止基于明矾的注射疫苗产生伊加方面起着核心作用, 靶向这些分子将通过增加伊加的产生来改善保护。目标1将侧重于 非粘膜部位髓样细胞先天性抑制伊加应答的潜在机制。目标2将 鉴定抑制该分子家族的药理学试剂靶向的细胞和信号通路 调节全身免疫后全身和粘膜免疫应答的诱导。目标3将 确定针对伊加反应的先天抑制因子的策略是否促进广泛的全身性和 粘膜免疫,可保护相关动物模型免受肠道病毒感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Prosper N Boyaka其他文献

Prosper N Boyaka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Prosper N Boyaka', 18)}}的其他基金

Targeting myeloid cells for regulation of alum-based immunity
靶向骨髓细胞调节明矾免疫
  • 批准号:
    10546495
  • 财政年份:
    2020
  • 资助金额:
    $ 65.83万
  • 项目类别:
Targeting myeloid cells for regulation of alum-based immunity
靶向骨髓细胞调节明矾免疫
  • 批准号:
    10333230
  • 财政年份:
    2020
  • 资助金额:
    $ 65.83万
  • 项目类别:
A novel lactic acid bacteria-based norovirus vaccine
一种新型乳酸菌诺如病毒疫苗
  • 批准号:
    9441705
  • 财政年份:
    2016
  • 资助金额:
    $ 65.83万
  • 项目类别:
A novel lactic acid bacteria-based norovirus vaccine
一种新型乳酸菌诺如病毒疫苗
  • 批准号:
    9084075
  • 财政年份:
    2016
  • 资助金额:
    $ 65.83万
  • 项目类别:
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells
肠上皮细胞对粘膜IgA和过敏性炎症的调节
  • 批准号:
    9265089
  • 财政年份:
    2015
  • 资助金额:
    $ 65.83万
  • 项目类别:
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells
肠上皮细胞对粘膜IgA和过敏性炎症的调节
  • 批准号:
    9095324
  • 财政年份:
    2015
  • 资助金额:
    $ 65.83万
  • 项目类别:
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells
肠上皮细胞对粘膜IgA和过敏性炎症的调节
  • 批准号:
    9473042
  • 财政年份:
    2015
  • 资助金额:
    $ 65.83万
  • 项目类别:
Regulation of mucosal IgA and allergic inflammation by intestinal epithelial cells
肠上皮细胞对粘膜IgA和过敏性炎症的调节
  • 批准号:
    8973366
  • 财政年份:
    2015
  • 资助金额:
    $ 65.83万
  • 项目类别:
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAX
基于 NALT 的炭疽免疫分子佐剂
  • 批准号:
    6615012
  • 财政年份:
    1998
  • 资助金额:
    $ 65.83万
  • 项目类别:
Alternative approaches for NALT-based immunity to respiratory pathogens
基于 NALT 的呼吸道病原体免疫替代方法
  • 批准号:
    7585079
  • 财政年份:
    1998
  • 资助金额:
    $ 65.83万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 65.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了